These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33862249)

  • 1. Current treatment options for HER2-positive breast cancer patients with brain metastases.
    Galanti D; Inno A; La Vecchia M; Borsellino N; Incorvaia L; Russo A; Gori S
    Crit Rev Oncol Hematol; 2021 May; 161():103329. PubMed ID: 33862249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.
    Giordano G; Griguolo G; Landriscina M; Meattini I; Carbone F; Leone A; Del Re M; Fogli S; Danesi R; Colamaria A; Dieci MV
    Crit Rev Oncol Hematol; 2023 Dec; 192():104185. PubMed ID: 37863404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib: an option for HER2-positive metastatic breast cancer.
    O'Shaughnessy JA; O'Regan R; Isaacs C
    Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-positive metastatic breast cancer: a comprehensive review.
    Exman P; Tolaney SM
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
    Metzger Filho O; Leone JP; Li T; Tan-Wasielewski Z; Trippa L; Barry WT; Younger J; Lawler E; Walker L; Freedman RA; Tolaney SM; Krop I; Winer EP; Lin NU
    Ann Oncol; 2020 Sep; 31(9):1231-1239. PubMed ID: 32461105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
    Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
    JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey N; Sandoval A; Mahtani R
    Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report.
    Yan F; Rinn KJ; Kullnat JA; Wu AY; Ennett MD; Scott EL; Kaplan HG
    J Natl Compr Canc Netw; 2022 Apr; 20(7):745-752. PubMed ID: 35405660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy for metastatic HER2-positive breast cancer.
    Bredin P; Walshe JM; Denduluri N
    Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
    J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
    Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
    Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
    Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
    Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
    Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
    Tarantino P; Prat A; Curigliano G
    Breast Cancer Res Treat; 2021 Feb; 185(3):879-881. PubMed ID: 33128191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic management of brain metastases in HER2+ breast cancer in 2022.
    Alder L; Sammons S; Van Swearingen AED; Anders CK
    Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
    O'Brien NA; Huang HKT; McDermott MSJ; Madrid AM; Luo T; Ayala R; Issakhanian S; Gong KW; Lu M; Zhang J; Slamon DJ
    Mol Cancer Ther; 2022 May; 21(5):751-761. PubMed ID: 35417017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.